MiR-182-, miR-191, miR-199a-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML)

ABSTRACT

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML).

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a divisional application of U.S. Ser. No. 12/523,915 having a 37CFR §1.371 filing date of Aug. 21, 2009, now U.S. Pat. No. 8,034,560issued Oct. 11, 2011, which was a national stage application filed under37 CFR 1.371 of international application PCT/US2008/001157 filed Jan.29, 2008 which claims the priority to U.S. Provisional Application Ser.No. 60/898,578 filed Jan. 31, 2007, the entire disclosures of which areexpressly incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant Nos. P01CA76259, P01 CA16058 and P01 CA 81534, awarded by National Institutes ofHealth. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

Acute myeloid leukemia (AML) is a heterogeneous disorder that includesmany entities with diverse genetic abnormalities and clinical features¹.The pathogenesis is known for relatively few types of leukemia².Patients with intermediate and poor risk cytogenetics represent themajority of AML; chemotherapy based regimens fail to cure most of thesepatients and stem cell transplantation is frequently the treatmentchoice³⁻⁴. Since allogeneic stem cell transplantation is not an optionfor many patients with high risk leukemia, there is a critical need toimprove our understanding of the biology of these leukemias and todevelop improved therapies.

Systematic high-throughput analysis of mRNA expression levels in AML hasdescribed new molecular subgroups of AML; some of these have beensuggested to predict outcome⁵⁻⁶. Despite this progress, focusing onknown genes will likely not suffice to uncover the molecular puzzle ofAML. The integration of a whole genome approach including non-codingRNAs may lead to an improved understanding of AML biology.

MicroRNAs (miRNAs) are non-coding RNAs of 19-25 nucleotides in lengththat regulate gene expression by inducing translational inhibition orcleavage of their target mRNA through base pairing to partially or fullycomplementary sites⁷. The miRNAs are involved in critical biologicalprocesses, including development, cell differentiation, apoptosis andproliferation⁸. Recently, miRNA expression has been linked tohematopoiesis and cancer⁹⁻¹¹. Calin et al. have shown deletions anddown-regulation of miR-15a and miR-16-1 in chronic lymphocyticleukemia¹². Several groups have reported changes in miRNA expression inlarge cell lymphoma¹³ and pediatric Burkitt lymphoma¹⁴. More recently,it has been shown that over-expression of miR-155 in B cells oftransgenic mice results in polyclonal B cell proliferation and B cellneoplasia¹⁵. These observations indicate that miRNAs are involved in theinitiation and progression of human cancer.

As disclosed herein, miRNA microarrays are used to profile a large setof AML patients with predominately intermediate and poor prognosis toinvestigate the association of miRNA profiles with cytogenetic groupsand clinical features.

Identification of microRNAs that are differentially-expressed in acutemyeloid leukemia cancer cells would aid in diagnosing, prognosticatingand treating leukemia. Furthermore, the identification of putativetargets of these miRNAs would help to unravel their pathogenic role. Inone broad aspect, there is provided herein provides novel methods andcompositions for the diagnosis, prognosis and treatment of acute myeloidleukemia.

SUMMARY OF THE INVENTION

The present invention is based, in part, on the identification of anacute myeloid leukemia cancer-specific signature of miRNAs that aredifferentially-expressed in breast cancer cells, relative to normalcontrol cells.

Accordingly, the invention encompasses methods of diagnosing whether asubject has, or is at risk for developing, acute myeloid leukemia (AML),comprising measuring the level of at least one miR gene product in atest sample from the subject, wherein an alteration in the level of themiR gene product in the test sample, relative to the level of acorresponding miR gene product in a control sample, is indicative of thesubject either having, or being at risk for developing, AML.

In certain embodiments, at least one miR gene product is miR-182,miR-191, or miR-199a.

The level of the at least one miR gene product can be measured using avariety of techniques that are well known to those of skill in the art.In one embodiment, the level of the at least one miR gene product ismeasured using Northern blot analysis. In another embodiment, the levelof the at least one miR gene product in the test sample is less than thelevel of the corresponding miR gene product in the control sample. Also,in another embodiment, the level of the at least one miR gene product inthe test sample can be greater than the level of the corresponding miRgene product in the control sample.

The invention also provides methods of diagnosing a AML associated withone or more prognostic markers in a subject, comprising measuring thelevel of at least one miR gene product in a AML sample from the subject,wherein an alteration in the level of the at least one miR gene productin the test sample, relative to the level of a corresponding miR geneproduct in a control sample, is indicative of the subject having a AMLassociated with the one or more prognostic markers. In one embodiment,the level of the at least one miR gene product is measured by reversetranscribing RNA from a test sample obtained from the subject to providea set of target oligodeoxynucleotides; hybridizing the targetoligodeoxynucleotides to a microarray comprising miRNA-specific probeoligonucleotides to provide a hybridization profile for the test sample;and, comparing the test sample hybridization profile to a hybridizationprofile generated from a control sample. An alteration in the signal ofat least one miRNA is indicative of the subject either having, or beingat risk for developing, AML.

The invention also encompasses methods of treating CLL in a subject,wherein the signal of at least one miRNA, relative to the signalgenerated from the control sample, is de-regulated (e.g.,down-regulated, up-regulated).

In certain embodiments, a microarray comprises miRNA-specific probeoligonucleotides for one or more miRNAs selected from the groupconsisting of miR-182, miR-191, or miR-199a and combinations thereof.

The invention also encompasses methods of diagnosing whether a subjecthas, or is at risk for developing, a AML associated with one or moreadverse prognostic markers in a subject, by reverse transcribing RNAfrom a test sample obtained from the subject to provide a set of targetoligodeoxynucleotides; hybridizing the target oligodeoxynucleotides to amicroarray comprising miRNA-specific probe oligonucleotides to provide ahybridization profile for the test sample; and, comparing the testsample hybridization profile to a hybridization profile generated from acontrol sample. An alteration in the signal is indicative of the subjecteither having, or being at risk for developing, the cancer.

The invention also encompasses methods of treating AML in a subject whohas AML in which at least one miR gene product is down-regulated orup-regulated in the cancer cells of the subject relative to controlcells. When the at least one miR gene product is down-regulated in thecancer cells, the method comprises administering to the subject aneffective amount of at least one isolated miR gene product, such thatproliferation of cancer cells in the subject is inhibited. When the atleast one miR gene product is up-regulated in the cancer cells, themethod comprises administering to the subject an effective amount of atleast one compound for inhibiting expression of the at least one miRgene product, such that proliferation of cancer cells in the subject isinhibited. In certain embodiments, the at least one isolated miR geneproduct is selected miR-182, miR-191, or miR-199a and combinationsthereof.

In related embodiments, the invention provides methods of treating AMLin a subject, comprising: determining the amount of at least one miRgene product in AML cells, relative to control cells; and altering theamount of miR gene product expressed in the AML cells by: administeringto the subject an effective amount of at least one isolated miR geneproduct, if the amount of the miR gene product expressed in the cancercells is less than the amount of the miR gene product expressed incontrol cells; or administering to the subject an effective amount of atleast one compound for inhibiting expression of the at least one miRgene product, if the amount of the miR gene product expressed in thecancer cells is greater than the amount of the miR gene productexpressed in control cells, such that proliferation of cancer cells inthe subject is inhibited. In certain embodiments, at least one isolatedmiR gene product is selected from the group consisting of miR-29,miR-181, and combinations thereof.

The invention further provides pharmaceutical compositions for treatingAML, comprising at least one isolated miR gene product and apharmaceutically-acceptable carrier. In a particular embodiment, thepharmaceutical compositions the at least one isolated miR gene productcorresponds to a miR gene product that is down-regulated in AML cellsrelative to suitable control cells. In particular embodiments, thepharmaceutical composition is selected from the group consisting ofmiR-182, miR-191, or miR-199a and combinations thereof. In anotherparticular embodiment, the pharmaceutical composition comprises at leastone miR expression inhibitor compound and a pharmaceutically-acceptablecarrier. Also, in a particular embodiment, the pharmaceuticalcomposition comprises at least one miR expression inhibitor compound isspecific for a miR gene product that is up-regulated in AML cellsrelative to suitable control cells.

In other embodiments, the present invention provides methods ofidentifying an anti-AML agent, comprising providing a test agent to acell and measuring the level of at least one miR gene product associatedwith decreased expression levels in AML cells, wherein an increase inthe level of the miR gene product in the cell, relative to a suitablecontrol cell, is indicative of the test agent being an anti-AML agent.In certain embodiments, the miR gene product is selected from the groupconsisting of at least one miR gene product is selected from the groupconsisting of the miRNAs as shown in any one of FIGS. 5-6, 8-18 and 21(Tables 1-2, 5-15 and 18). In a particular embodiment, least one miRgene product is selected from the group consisting of miR-20, miR-25,miR-191, miR-199a, and miR-199b and combinations thereof.

The present invention also provides methods of identifying an anti-AMLagent, comprising providing a test agent to a cell and measuring thelevel of at least one miR gene product associated with increasedexpression levels in AML cells, wherein an decrease in the level of themiR gene product in the cell, relative to a suitable control cell, isindicative of the test agent being an anti-AML agent. In a particularembodiment, the miR gene product is selected from the group consistingof miR-29, miR-181 and combinations thereof.

Additional advantages, objects, and features of the invention will beset forth in part in the description which follows and in part willbecome apparent to those having ordinary skill in the art uponexamination of the following or may be learned from practice of theinvention. The objects and advantages of the invention may be realizedand attained as particularly pointed out in the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-F. Validation of microarray data by quantification of maturemiRNAs by qRT-PCR.

FIG. 1A. MicroRNA (miRNA) expression of 6 AML samples with respect toCD34+ progenitors. Results are presented as fold change of the miRNAexpression in AML samples with respect to CD34+ expression values, afternormalization (Ct) with let-7i and 2^(ΔCt) conversion¹⁸ (thin barsrepresent standard deviations).

FIG. 1B. Validation of the microarrays data using qRT-PCR. Scatter plotshowing the negative correlation between the miRNA micro array sexpression values (2 log) and the normalized qRT-PCR OCt values (logscale) for each sample (Pearson correlation coefficient R=0.88 p<0.001).The solid pink line represents the predicted Y. The lower the qRT-PCR(Ct values), the higher the expression level of the miRNA. For example,the points at the bottom right have low ΔCt values (high expression) andcorrespond with high micro array (chip) values.

FIG. 1C. mRNA expression in mature and hematopoietic committedprecursors with respect to CD34+ stem cells. The results are presentedas fold change in the average miRNA expression of the different matureand committed precursors with respect to that of CD34+ cells afternormalization with 18S and 2^(ΔCt) conversion.

FIG. 1D. Average qRT-PCR expression of miR-181b in AML samples groupedaccording the FAB classification; the numbers of patient samples in eachcategory are as follows; M0-M1 (6), M2 (8) and M 6M7 (5).

FIG. 1E. Average miR-10 qRT-PCR expression in AML patients with normalkaryotype (10) vs. other abnormal karyotype (26).

FIG. 1F. Average expression of miR-126 in patients with complexkaryotype (6) and in patients with other cytogenetic abnormalities (22)by qRT-PCR. The miRNA expression between the different groups wascompared by using t-Test (SPSS).

FIGS. 2A-D. MicroRNAs associated with overall survival in newlydiagnosed patients with AML. Kaplan-Meier estimates of overall survivalfor 122 AML patients with high or low expression of miR-20 (FIG. 2A) andmiR-25 (FIG. 2B) detected by micro arrays. The log-rank test was used tocompare differences between survival curves. An independent set of 36AML patients with similar clinical characteristics (FIG. 4 (Table 1))was used to validate the outcome predictive power of miR-20 and miR-25by using a different technology (miRNA qRT-PCR). Kaplan-Meier estimatesof overall survival for the 36 AML patients with high or low expressionof miR-20 (FIG. 2C) and miR-25 (FIG. 2D) detected by qRT-PCR are shown.Hazard ratios with 95% confidence intervals (CI 95%) were obtained bythe Kaplan-Meier method.

FIG. 3A. Average qRT-PCR of miR-181b and miR-135a expression in bonemarrow erythrocytic/megakaryocytic precursors and peripheral bloodmature granulocytes/monocytes obtained from four different healthydonors. Results are shown as the fold change in the miRNA expression inthe different lineages with respect to that of miR-181b and miR-135b infour CD34+ cells.

FIG. 3B. Average qRT-PCR expression values of miR-30c in 10 patientswith normal karyotype and in 22 patients with abnormal karyotype. ThemiRNA expression values from the two groups (Normal vs. abnormalkaryotype) were compared using t-Test (SPSS).

FIG. 3C. Average miR-29b expression in AML patients who receivedinduction chemotherapy with idarubicin and cytarabine by qRT-PCR in 12independent patients with newly diagnosed AML that achieve completeremission (6) or have failure to achieve induction chemotherapy (6). ThemiRNA expression values from the two groups (CR vs. failure) werecompared using t-Test (SPSS).

FIG. 4. Table 1. Clinical and cytogenetics characterizations of 158newly diagnosed patients with AML.

FIG. 5. Table 2. MicroRNAs associated with FAB classification andcytogenetics.

FIG. 6. Table 3. MicroRNAs associated with overall survival in 122patients with AML.

FIG. 7. Table 4. Housekeeping gene probes used in the normalization ofmicroarray data.

FIG. 8. Table 5. miRNAs differentially expressed between CD 34+ cellsand the 122 patients with AML.

FIG. 9 (Table 6). miRNAs differentially expressed in AML FAB M0-M1compared with others AML FAB subtypes.

FIG. 10. Table 7. miRNAs differentially expressed in AML FAB M3 [t (15;17)].

FIG. 11. Table 8. miRNAs differentially expressed in A ML FAB M4 and M5compared with other AML.

FIG. 12. Table 9. miRNAs differentially expressed in AML FAB M6 and M7compared with other AML.

FIG. 13. Table 10. miRNAs associated with high WBC, and peripheral blood(PB) and bone marrow (BM) blasts.

FIG. 14. Table 11. miRNAs differentially expressed in normal karyotypeAML compared with other AML.

FIG. 15. Table 12. miRNAs associated with 11q23 rearrangements.

FIG. 16. Table 13. miRNAs differentially expressed in patients withcomplex karyotype compared with non-complex or normal karyotype.

FIG. 17. Table 14. miRNAs associated with chromosome 7.

FIG. 18. Table 15. miRNAs associated with trisomy 8.

FIG. 19. Table 16. Characteristics of 54 patients with AML at firstrelapse after initial induction chemotherapy or primary refractorydisease.

FIG. 20. Table 17. Clinical characteristics of the 24 patients treatedwith idarubicin and cytarabine.

FIG. 21. Table 18. miRNAs associated with response to Idarubicin andcytarabine.

DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the identification ofparticular microRNAs having altered expression in acute myeloid leukemia(AML) cancer cells relative to normal control cells, and on associationof these microRNAs with particular diagnostic, prognostic andtherapeutic features.

As used herein interchangeably, a “miR gene product,” “microRNA,” “miR,”or “miRNA” refers to the unprocessed or processed RNA transcript from amiR gene. As the miR gene products are not translated into protein, theterm “miR gene products” does not include proteins. The unprocessed miRgene transcript is also called a “miR precursor,” and typicallycomprises an RNA transcript of about 70-100 nucleotides in length. ThemiR precursor can be processed by digestion with an RNAse (for example,Dicer, Argonaut, RNAse III (e.g., E. coli RNAse III)) into an active19-25 nucleotide RNA molecule. This active 19-25 nucleotide RNA moleculeis also called the “processed” miR gene transcript or “mature” miRNA.

The active 19-25 nucleotide RNA molecule can be obtained from the miRprecursor through natural processing routes (e.g., using intact cells orcell lysates) or by synthetic processing routes (e.g., using isolatedprocessing enzymes, such as isolated Dicer, Argonaut, or RNAse III). Itis understood that the active 19-25 nucleotide RNA molecule can also beproduced directly by biological or chemical synthesis, without having tobe processed from the miR precursor. When a microRNA is referred toherein by name, the name corresponds to both the precursor and matureforms, unless otherwise indicated.

The present invention encompasses methods of diagnosing whether asubject has, or is at risk for developing, AML, comprising measuring thelevel of at least one miR gene product in a test sample from the subjectand comparing the level of the miR gene product in the test sample tothe level of a corresponding miR gene product in a control sample. Asused herein, a “subject” can be any mammal that has, or is suspected ofhaving, AML. In a preferred embodiment, the subject is a human who has,or is suspected of having, AML.

The level of at least one miR gene product can be measured in cells of abiological sample obtained from the subject. For example, a tissuesample can be removed from a subject suspected of having AML byconventional biopsy techniques. In another embodiment, a blood samplecan be removed from the subject, and white blood cells can be isolatedfor DNA extraction by standard techniques. The blood or tissue sample ispreferably obtained from the subject prior to initiation ofradiotherapy, chemotherapy or other therapeutic treatment. Acorresponding control tissue or blood sample, or a control referencesample, can be obtained from unaffected tissues of the subject, from anormal human individual or population of normal individuals, or fromcultured cells corresponding to the majority of cells in the subject'ssample. The control tissue or blood sample is then processed along withthe sample from the subject, so that the levels of miR gene productproduced from a given miR gene in cells from the subject's sample can becompared to the corresponding miR gene product levels from cells of thecontrol sample. Alternatively, a reference sample can be obtained andprocessed separately (e.g., at a different time) from the test sampleand the level of a miR gene product produced from a given miR gene incells from the test sample can be compared to the corresponding miR geneproduct level from the reference sample.

In one embodiment, the level of the at least one miR gene product in thetest sample is greater than the level of the corresponding miR geneproduct in the control sample (i.e., expression of the miR gene productis “up-regulated”). As used herein, expression of a miR gene product is“up-regulated” when the amount of miR gene product in a cell or tissuesample from a subject is greater than the amount of the same geneproduct in a control cell or tissue sample. In another embodiment, thelevel of the at least one miR gene product in the test sample is lessthan the level of the corresponding miR gene product in the controlsample (i.e., expression of the miR gene product is “down-regulated”).As used herein, expression of a miR gene is “down-regulated” when theamount of miR gene product produced from that gene in a cell or tissuesample from a subject is less than the amount produced from the samegene in a control cell or tissue sample. The relative miR geneexpression in the control and normal samples can be determined withrespect to one or more RNA expression standards. The standards cancomprise, for example, a zero miR gene expression level, the miR geneexpression level in a standard cell line, the miR gene expression levelin unaffected tissues of the subject, or the average level of miR geneexpression previously obtained for a population of normal humancontrols.

An alteration (i.e., an increase or decrease) in the level of a miR geneproduct in the sample obtained from the subject, relative to the levelof a corresponding miR gene product in a control sample, is indicativeof the presence of AML cancer in the subject. In one embodiment, thelevel of at least one miR gene product in the test sample is greaterthan the level of the corresponding miR gene product in the controlsample. In another embodiment, the level of at least one miR geneproduct in the test sample is less than the level of the correspondingmiR gene product in the control sample.

In a certain embodiment, the at least one miR gene product is selectedfrom the groups as shown in the Tables and Figures herein.

The level of a miR gene product in a sample can be measured using anytechnique that is suitable for detecting RNA expression levels in abiological sample. Suitable techniques (e.g., Northern blot analysis,RT-PCR, in situ hybridization) for determining RNA expression levels ina biological sample (e.g., cells, tissues) are well known to those ofskill in the art. In a particular embodiment, the level of at least onemiR gene product is detected using Northern blot analysis. For example,total cellular RNA can be purified from cells by homogenization in thepresence of nucleic acid extraction buffer, followed by centrifugation.Nucleic acids are precipitated, and DNA is removed by treatment withDNase and precipitation. The RNA molecules are then separated by gelelectrophoresis on agarose gels according to standard techniques, andtransferred to nitrocellulose filters. The RNA is then immobilized onthe filters by heating. Detection and quantification of specific RNA isaccomplished using appropriately labeled DNA or RNA probes complementaryto the RNA in question. See, for example, Molecular Cloning: ALaboratory Manual, J. Sambrook et al., eds., 2nd edition, Cold SpringHarbor Laboratory Press, 1989, Chapter 7, the entire disclosure of whichis incorporated by reference.

Suitable probes (e.g., DNA probes, RNA probes) for Northern blothybridization of a given miR gene product can be produced from thenucleic acid sequences provided in the Tables herein and include, butare not limited to, probes having at least about 70%, 75%, 80%, 85%,90%, 95%, 98% or 99% complementarity to a miR gene product of interest,as well as probes that have complete complementarity to a miR geneproduct of interest. Methods for preparation of labeled DNA and RNAprobes, and the conditions for hybridization thereof to targetnucleotide sequences, are described in Molecular Cloning: A LaboratoryManual, J. Sambrook et al., eds., 2nd edition, Cold Spring HarborLaboratory Press, 1989, Chapters 10 and 11, the disclosures of which areincorporated herein by reference.

For example, the nucleic acid probe can be labeled with, e.g., aradionuclide, such as ³H, ³²P, ³³P, ¹⁴C, or ³⁵S; a heavy metal; a ligandcapable of functioning as a specific binding pair member for a labeledligand (e.g., biotin, avidin or an antibody); a fluorescent molecule; achemiluminescent molecule; an enzyme or the like.

Probes can be labeled to high specific activity by either the nicktranslation method of Rigby et al. (1977), J. Mol. Biol. 113:237-251 orby the random priming method of Fienberg et al. (1983), Anal. Biochem.132:6-13, the entire disclosures of which are incorporated herein byreference. The latter is the method of choice for synthesizing³²P-labeled probes of high specific activity from single-stranded DNA orfrom RNA templates. For example, by replacing preexisting nucleotideswith highly radioactive nucleotides according to the nick translationmethod, it is possible to prepare ³²P-labeled nucleic acid probes with aspecific activity well in excess of 10⁸ cpm/microgram. Autoradiographicdetection of hybridization can then be performed by exposing hybridizedfilters to photographic film. Densitometric scanning of the photographicfilms exposed by the hybridized filters provides an accurate measurementof miR gene transcript levels. Using another approach, miR genetranscript levels can be quantified by computerized imaging systems,such as the Molecular Dynamics 400-B 2D Phosphorimager available fromAmersham Biosciences, Piscataway, N.J.

Where radionuclide labeling of DNA or RNA probes is not practical, therandom-primer method can be used to incorporate an analogue, forexample, the dTTP analogue5-(N—(N-biotinyl-epsilon-aminocaproyl)-3-aminoallyl)deoxyuridinetriphosphate, into the probe molecule. The biotinylated probeoligonucleotide can be detected by reaction with biotin-bindingproteins, such as avidin, streptavidin and antibodies (e.g., anti-biotinantibodies) coupled to fluorescent dyes or enzymes that produce colorreactions.

In addition to Northern and other RNA hybridization techniques,determining the levels of RNA transcripts can be accomplished using thetechnique of in situ hybridization. This technique requires fewer cellsthan the Northern blotting technique and involves depositing whole cellsonto a microscope cover slip and probing the nucleic acid content of thecell with a solution containing radioactive or otherwise labeled nucleicacid (e.g., cDNA or RNA) probes. This technique is particularlywell-suited for analyzing tissue biopsy samples from subjects. Thepractice of the in situ hybridization technique is described in moredetail in U.S. Pat. No. 5,427,916, the entire disclosure of which isincorporated herein by reference. Suitable probes for in situhybridization of a given miR gene product can be produced from thenucleic acid sequences provided in the Tables herein, and include, butare not limited to, probes having at least about 70%, 75%, 80%, 85%,90%, 95%, 98% or 99% complementarity to a miR gene product of interest,as well as probes that have complete complementarity to a miR geneproduct of interest, as described above.

The relative number of miR gene transcripts in cells can also bedetermined by reverse transcription of miR gene transcripts, followed byamplification of the reverse-transcribed transcripts by polymerase chainreaction (RT-PCR). The levels of miR gene transcripts can be quantifiedin comparison with an internal standard, for example, the level of mRNAfrom a “housekeeping” gene present in the same sample. A suitable“housekeeping” gene for use as an internal standard includes, e.g.,myosin or glyceraldehyde-3-phosphate dehydrogenase (G3PDH). Methods forperforming quantitative and semi-quantitative RT-PCR, and variationsthereof, are well known to those of skill in the art.

In some instances, it may be desirable to simultaneously determine theexpression level of a plurality of different miR gene products in asample. In other instances, it may be desirable to determine theexpression level of the transcripts of all known miR genes correlatedwith a cancer. Assessing cancer-specific expression levels for hundredsof miR genes or gene products is time consuming and requires a largeamount of total RNA (e.g., at least 20 μg for each Northern blot) andautoradiographic techniques that require radioactive isotopes.

To overcome these limitations, an oligolibrary, in microchip format(i.e., a microarray), may be constructed containing a set ofoligonucleotide (e.g., oligodeoxynucleotide) probes that are specificfor a set of miR genes. Using such a microarray, the expression level ofmultiple microRNAs in a biological sample can be determined by reversetranscribing the RNAs to generate a set of target oligodeoxynucleotides,and hybridizing them to probe the oligonucleotides on the microarray togenerate a hybridization, or expression, profile. The hybridizationprofile of the test sample can then be compared to that of a controlsample to determine which microRNAs have an altered expression level inAML cancer cells. As used herein, “probe oligonucleotide” or “probeoligodeoxynucleotide” refers to an oligonucleotide that is capable ofhybridizing to a target oligonucleotide. “Target oligonucleotide” or“target oligodeoxynucleotide” refers to a molecule to be detected (e.g.,via hybridization). By “miR-specific probe oligonucleotide” or “probeoligonucleotide specific for a miR” is meant a probe oligonucleotidethat has a sequence selected to hybridize to a specific miR geneproduct, or to a reverse transcript of the specific miR gene product.

An “expression profile” or “hybridization profile” of a particularsample is essentially a fingerprint of the state of the sample; whiletwo states may have any particular gene similarly expressed, theevaluation of a number of genes simultaneously allows the generation ofa gene expression profile that is unique to the state of the cell. Thatis, normal tissue may be distinguished from AML cells, and within AMLcells, different prognosis states (for example, good or poor long termsurvival prospects) may be determined. By comparing expression profilesof AML cells in different states, information regarding which genes areimportant (including both up- and down-regulation of genes) in each ofthese states is obtained. The identification of sequences that aredifferentially expressed in AML cells or normal cells, as well asdifferential expression resulting in different prognostic outcomes,allows the use of this information in a number of ways. For example, aparticular treatment regime may be evaluated (e.g., to determine whethera chemotherapeutic drug acts to improve the long-term prognosis in aparticular patient). Similarly, diagnosis may be done or confirmed bycomparing patient samples with known expression profiles. Furthermore,these gene expression profiles (or individual genes) allow screening ofdrug candidates that suppress the AML expression profile or convert apoor prognosis profile to a better prognosis profile.

Accordingly, the invention provides methods of diagnosing whether asubject has, or is at risk for developing, AML, comprising reversetranscribing RNA from a test sample obtained from the subject to providea set of target oligodeoxynucleotides, hybridizing the targetoligodeoxynucleotides to a microarray comprising miRNA-specific probeoligonucleotides to provide a hybridization profile for the test sample,and comparing the test sample hybridization profile to a hybridizationprofile generated from a control sample, wherein an alteration in thesignal of at least one miRNA is indicative of the subject either having,or being at risk for developing, AML. In one embodiment, the microarraycomprises miRNA-specific probe oligonucleotides for a substantialportion of all known human miRNAs.

In a particular embodiment, the microarray comprises miRNA-specificprobe oligonucleotides for one or more miRNAs selected from the groupconsisting of the miRNAs as shown in any one of FIGS. 5-6, 8-18 and 21(Tables 1-2, 5-15 and 18). In one embodiment, at least one miR geneproduct is selected from the group consisting of miR-20, miR-25,miR-191, miR-199a, and miR-199b and combinations thereof.

The microarray can be prepared from gene-specific oligonucleotide probesgenerated from known miRNA sequences. The array may contain twodifferent oligonucleotide probes for each miRNA, one containing theactive, mature sequence and the other being specific for the precursorof the miRNA. The array may also contain controls, such as one or moremouse sequences differing from human orthologs by only a few bases,which can serve as controls for hybridization stringency conditions.tRNAs and other RNAs (e.g., rRNAs, miRNAs) from both species may also beprinted on the microchip, providing an internal, relatively stable,positive control for specific hybridization. One or more appropriatecontrols for non-specific hybridization may also be included on themicrochip. For this purpose, sequences are selected based upon theabsence of any homology with any known miRNAs.

The microarray may be fabricated using techniques known in the art. Forexample, probe oligonucleotides of an appropriate length, e.g., 40nucleotides, are 5′-amine modified at position C6 and printed usingcommercially available microarray systems, e.g., the GeneMachineOmniGrid™ 100 Microarrayer and Amersham CodeLink™ activated slides.Labeled cDNA oligomer corresponding to the target RNAs is prepared byreverse transcribing the target RNA with labeled primer. Following firststrand synthesis, the RNA/DNA hybrids are denatured to degrade the RNAtemplates. The labeled target cDNAs thus prepared are then hybridized tothe microarray chip under hybridizing conditions, e.g., 6×SSPE/30%formamide at 25° C. for 18 hours, followed by washing in 0.75×TNT at 37°C. for 40 minutes. At positions on the array where the immobilized probeDNA recognizes a complementary target cDNA in the sample, hybridizationoccurs. The labeled target cDNA marks the exact position on the arraywhere binding occurs, allowing automatic detection and quantification.The output consists of a list of hybridization events, indicating therelative abundance of specific cDNA sequences, and therefore therelative abundance of the corresponding complementary miRs, in thepatient sample. According to one embodiment, the labeled cDNA oligomeris a biotin-labeled cDNA, prepared from a biotin-labeled primer. Themicroarray is then processed by direct detection of thebiotin-containing transcripts using, e.g., Streptavidin-Alexa647conjugate, and scanned utilizing conventional scanning methods. Imageintensities of each spot on the array are proportional to the abundanceof the corresponding miR in the patient sample.

The use of the array has several advantages for miRNA expressiondetection. First, the global expression of several hundred genes can beidentified in the same sample at one time point. Second, through carefuldesign of the oligonucleotide probes, expression of both mature andprecursor molecules can be identified. Third, in comparison withNorthern blot analysis, the chip requires a small amount of RNA, andprovides reproducible results using 2.5 μg of total RNA. The relativelylimited number of miRNAs (a few hundred per species) allows theconstruction of a common microarray for several species, with distinctoligonucleotide probes for each. Such a tool would allow for analysis oftrans-species expression for each known miR under various conditions.

In addition to use for quantitative expression level assays of specificmiRs, a microchip containing miRNA-specific probe oligonucleotidescorresponding to a substantial portion of the miRNome, preferably theentire miRNome, may be employed to carry out miR gene expressionprofiling, for analysis of miR expression patterns. Distinct miRsignatures can be associated with established disease markers, ordirectly with a disease state.

According to the expression profiling methods described herein, totalRNA from a sample from a subject suspected of having a cancer (e.g.,AML) is quantitatively reverse transcribed to provide a set of labeledtarget oligodeoxynucleotides complementary to the RNA in the sample. Thetarget oligodeoxynucleotides are then hybridized to a microarraycomprising miRNA-specific probe oligonucleotides to provide ahybridization profile for the sample. The result is a hybridizationprofile for the sample representing the expression pattern of miRNA inthe sample. The hybridization profile comprises the signal from thebinding of the target oligodeoxynucleotides from the sample to themiRNA-specific probe oligonucleotides in the microarray. The profile maybe recorded as the presence or absence of binding (signal vs. zerosignal). More preferably, the profile recorded includes the intensity ofthe signal from each hybridization. The profile is compared to thehybridization profile generated from a normal, e.g., noncancerous,control sample. An alteration in the signal is indicative of thepresence of, or propensity to develop, cancer in the subject.

Other techniques for measuring miR gene expression are also within theskill in the art, and include various techniques for measuring rates ofRNA transcription and degradation.

The invention also provides methods of determining the prognosis of asubject with AML cancer, comprising measuring the level of at least onemiR gene product, which is associated with a particular prognosis in AML(e.g., a good or positive prognosis, a poor or adverse prognosis), in atest sample from the subject. According to these methods, an alterationin the level of a miR gene product that is associated with a particularprognosis, in the test sample, as compared to the level of acorresponding miR gene product in a control sample, is indicative of thesubject having AML with a particular prognosis. In one embodiment, themiR gene product is associated with an adverse (i.e., poor) prognosis.Examples of an adverse prognosis include, but are not limited to, lowsurvival rate and rapid disease progression.

In certain embodiments, the level of the at least one miR gene productis measured by reverse transcribing RNA from a test sample obtained fromthe subject to provide a set of target oligodeoxynucleotides,hybridizing the target oligodeoxynucleotides to a microarray thatcomprises miRNA-specific probe oligonucleotides to provide ahybridization profile for the test sample, and comparing the test samplehybridization profile to a hybridization profile generated from acontrol sample.

Without wishing to be bound by any one theory, it is believed thatalterations in the level of one or more miR gene products in cells canresult in the deregulation of one or more intended targets for thesemiRs, which can lead to the formation of AML. Therefore, altering thelevel of the miR gene product (e.g., by decreasing the level of a miRthat is up-regulated in AML cancer cells, by increasing the level of amiR that is down-regulated in AML cancer cells) may successfully treatthe AML cancer.

Accordingly, the present invention encompasses methods of treating AMLin a subject, wherein at least one miR gene product is deregulated(e.g., down-regulated, up-regulated) in the cells (e.g., AML cancercells) of the subject. In one embodiment, the level of at least one miRgene product in a test sample (e.g., AML cancer sample) is greater thanthe level of the corresponding miR gene product in a control sample. Inanother embodiment, the level of at least one miR gene product in a testsample (e.g., AML cancer sample) is less than the level of thecorresponding miR gene product in a control sample. When the at leastone isolated miR gene product is down-regulated in the AML cancer cells,the method comprises administering an effective amount of the at leastone isolated miR gene product, or an isolated variant orbiologically-active fragment thereof, such that proliferation of cancercells in the subject is inhibited. For example, when a miR gene productis down-regulated in a cancer cell in a subject, administering aneffective amount of an isolated miR gene product to the subject caninhibit proliferation of the cancer cell. The isolated miR gene productthat is administered to the subject can be identical to an endogenouswild-type miR gene product (e.g., a miR gene product shown in the Tablesherein) that is down-regulated in the cancer cell or it can be a variantor biologically-active fragment thereof.

As defined herein, a “variant” of a miR gene product refers to a miRNAthat has less than 100% identity to a corresponding wild-type miR geneproduct and possesses one or more biological activities of thecorresponding wild-type miR gene product. Examples of such biologicalactivities include, but are not limited to, inhibition of expression ofa target RNA molecule (e.g., inhibiting translation of a target RNAmolecule, modulating the stability of a target RNA molecule, inhibitingprocessing of a target RNA molecule) and inhibition of a cellularprocess associated with AML (e.g., cell differentiation, cell growth,cell death). These variants include species variants and variants thatare the consequence of one or more mutations (e.g., a substitution, adeletion, an insertion) in a miR gene. In certain embodiments, thevariant is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%identical to a corresponding wild-type miR gene product.

As defined herein, a “biologically-active fragment” of a miR geneproduct refers to an RNA fragment of a miR gene product that possessesone or more biological activities of a corresponding wild-type miR geneproduct. As described above, examples of such biological activitiesinclude, but are not limited to, inhibition of expression of a targetRNA molecule and inhibition of a cellular process associated with AML.In certain embodiments, the biologically-active fragment is at leastabout 5, 7, 10, 12, 15, or 17 nucleotides in length. In a particularembodiment, an isolated miR gene product can be administered to asubject in combination with one or more additional anti-cancertreatments. Suitable anti-cancer treatments include, but are not limitedto, chemotherapy, radiation therapy and combinations thereof (e.g.,chemoradiation).

When the at least one isolated miR gene product is up-regulated in thecancer cells, the method comprises administering to the subject aneffective amount of a compound that inhibits expression of the at leastone miR gene product, such that proliferation of AML cancer cells isinhibited. Such compounds are referred to herein as miR geneexpression-inhibition compounds. Examples of suitable miR geneexpression-inhibition compounds include, but are not limited to, thosedescribed herein (e.g., double-stranded RNA, antisense nucleic acids andenzymatic RNA molecules). In a particular embodiment, a miR geneexpression-inhibiting compound can be administered to a subject incombination with one or more additional anti-cancer treatments. Suitableanti-cancer treatments include, but are not limited to, chemotherapy,radiation therapy and combinations thereof (e.g., chemoradiation).

In a certain embodiment, the isolated miR gene product that isderegulated in AML cancer is selected from the group consisting of themiRNAs as shown in any one of FIGS. 5-6, 8-18 and 21 (Tables 1-2, 5-15and 18).

In a particular embodiment, the at least one miR gene product isselected from the group consisting of miR-20, miR-25, miR-191, miR-199a,and miR-199b and combinations thereof.

The terms “treat”, “treating” and “treatment”, as used herein, refer toameliorating symptoms associated with a disease or condition, forexample, AML cancer, including preventing or delaying the onset of thedisease symptoms, and/or lessening the severity or frequency of symptomsof the disease or condition. The terms “subject” and “individual” aredefined herein to include animals, such as mammals, including, but notlimited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits,guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline,rodent, or murine species. In a preferred embodiment, the animal is ahuman.

As used herein, an “effective amount” of an isolated miR gene product isan amount sufficient to inhibit proliferation of a cancer cell in asubject suffering from AML cancer. One skilled in the art can readilydetermine an effective amount of a miR gene product to be administeredto a given subject, by taking into account factors, such as the size andweight of the subject; the extent of disease penetration; the age,health and sex of the subject; the route of administration; and whetherthe administration is regional or systemic.

For example, an effective amount of an isolated miR gene product can bebased on the approximate weight of a tumor mass to be treated. Theapproximate weight of a tumor mass can be determined by calculating theapproximate volume of the mass, wherein one cubic centimeter of volumeis roughly equivalent to one gram. An effective amount of the isolatedmiR gene product based on the weight of a tumor mass can be in the rangeof about 10-500 micrograms/gram of tumor mass. In certain embodiments,the tumor mass can be at least about 10 micrograms/gram of tumor mass,at least about 60 micrograms/gram of tumor mass or at least about 100micrograms/gram of tumor mass.

An effective amount of an isolated miR gene product can also be based onthe approximate or estimated body weight of a subject to be treated.Preferably, such effective amounts are administered parenterally orenterally, as described herein. For example, an effective amount of theisolated miR gene product that is administered to a subject can rangefrom about 5-3000 micrograms/kg of body weight, from about 700-1000micrograms/kg of body weight, or greater than about 1000 micrograms/kgof body weight.

One skilled in the art can also readily determine an appropriate dosageregimen for the administration of an isolated miR gene product to agiven subject. For example, a miR gene product can be administered tothe subject once (e.g., as a single injection or deposition).Alternatively, a miR gene product can be administered once or twicedaily to a subject for a period of from about three to abouttwenty-eight days, more particularly from about seven to about ten days.In a particular dosage regimen, a miR gene product is administered oncea day for seven days. Where a dosage regimen comprises multipleadministrations, it is understood that the effective amount of the miRgene product administered to the subject can comprise the total amountof gene product administered over the entire dosage regimen.

As used herein, an “isolated” miR gene product is one that issynthesized, or altered or removed from the natural state through humanintervention. For example, a synthetic miR gene product, or a miR geneproduct partially or completely separated from the coexisting materialsof its natural state, is considered to be “isolated.” An isolated miRgene product can exist in a substantially-purified form, or can exist ina cell into which the miR gene product has been delivered. Thus, a miRgene product that is deliberately delivered to, or expressed in, a cellis considered an “isolated” miR gene product. A miR gene productproduced inside a cell from a miR precursor molecule is also consideredto be an “isolated” molecule. According to the invention, the isolatedmiR gene products described herein can be used for the manufacture of amedicament for treating AML cancer in a subject (e.g., a human).

Isolated miR gene products can be obtained using a number of standardtechniques. For example, the miR gene products can be chemicallysynthesized or recombinantly produced using methods known in the art. Inone embodiment, miR gene products are chemically synthesized usingappropriately protected ribonucleoside phosphoramidites and aconventional DNA/RNA synthesizer. Commercial suppliers of synthetic RNAmolecules or synthesis reagents include, e.g., Proligo (Hamburg,Germany), Dharmacon Research (Lafayette, Colo., U.S.A.), Pierce Chemical(part of Perbio Science, Rockford, Ill., U.S.A.), Glen Research(Sterling, Va., U.S.A.), ChemGenes (Ashland, Mass., U.S.A.) and Cruachem(Glasgow, UK).

Alternatively, the miR gene products can be expressed from recombinantcircular or linear DNA plasmids using any suitable promoter. Suitablepromoters for expressing RNA from a plasmid include, e.g., the U6 or H1RNA pol III promoter sequences, or the cytomegalovirus promoters.Selection of other suitable promoters is within the skill in the art.The recombinant plasmids of the invention can also comprise inducible orregulatable promoters for expression of the miR gene products in cancercells.

The miR gene products that are expressed from recombinant plasmids canbe isolated from cultured cell expression systems by standardtechniques. The miR gene products that are expressed from recombinantplasmids can also be delivered to, and expressed directly in, the cancercells. The use of recombinant plasmids to deliver the miR gene productsto cancer cells is discussed in more detail below.

The miR gene products can be expressed from a separate recombinantplasmid, or they can be expressed from the same recombinant plasmid. Inone embodiment, the miR gene products are expressed as RNA precursormolecules from a single plasmid, and the precursor molecules areprocessed into the functional miR gene product by a suitable processingsystem, including, but not limited to, processing systems extant withina cancer cell. Other suitable processing systems include, e.g., the invitro Drosophila cell lysate system (e.g., as described in U.S.Published Patent Application No. 2002/0086356 to Tuschl et al., theentire disclosure of which is incorporated herein by reference) and theE. coli RNAse III system (e.g., as described in U.S. Published PatentApplication No. 2004/0014113 to Yang et al., the entire disclosure ofwhich is incorporated herein by reference).

Selection of plasmids suitable for expressing the miR gene products,methods for inserting nucleic acid sequences into the plasmid to expressthe gene products, and methods of delivering the recombinant plasmid tothe cells of interest are within the skill in the art. See, for example,Zeng et al. (2002), Molecular Cell 9:1327-1333; Tuschl (2002), Nat.Biotechnol, 20:446-448; Brummelkamp et al. (2002), Science 296:550-553;Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500; Paddison et al.(2002), Genes Dev. 16:948-958; Lee et al. (2002), Nat. Biotechnol.20:500-505; and Paul et al. (2002), Nat. Biotechnol. 20:505-508, theentire disclosures of which are incorporated herein by reference.

In one embodiment, a plasmid expressing the miR gene products comprisesa sequence encoding a miR precursor RNA under the control of the CMVintermediate-early promoter. As used herein, “under the control” of apromoter means that the nucleic acid sequences encoding the miR geneproduct are located 3′ of the promoter, so that the promoter caninitiate transcription of the miR gene product coding sequences.

The miR gene products can also be expressed from recombinant viralvectors. It is contemplated that the miR gene products can be expressedfrom two separate recombinant viral vectors, or from the same viralvector. The RNA expressed from the recombinant viral vectors can eitherbe isolated from cultured cell expression systems by standardtechniques, or can be expressed directly in cancer cells. The use ofrecombinant viral vectors to deliver the miR gene products to cancercells is discussed in more detail below.

The recombinant viral vectors of the invention comprise sequencesencoding the miR gene products and any suitable promoter for expressingthe RNA sequences. Suitable promoters include, but are not limited to,the U6 or H1 RNA pol III promoter sequences, or the cytomegaloviruspromoters. Selection of other suitable promoters is within the skill inthe art. The recombinant viral vectors of the invention can alsocomprise inducible or regulatable promoters for expression of the miRgene products in a cancer cell.

Any viral vector capable of accepting the coding sequences for the miRgene products can be used; for example, vectors derived from adenovirus(AV); adeno-associated virus (AAV); retroviruses (e.g., lentiviruses(LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like.The tropism of the viral vectors can be modified by pseudotyping thevectors with envelope proteins or other surface antigens from otherviruses, or by substituting different viral capsid proteins, asappropriate.

For example, lentiviral vectors of the invention can be pseudotyped withsurface proteins from vesicular stomatitis virus (VSV), rabies, Ebola,Mokola, and the like. AAV vectors of the invention can be made to targetdifferent cells by engineering the vectors to express different capsidprotein serotypes. For example, an AAV vector expressing a serotype 2capsid on a serotype 2 genome is called AAV 2/2. This serotype 2 capsidgene in the AAV 2/2 vector can be replaced by a serotype 5 capsid geneto produce an AAV 2/5 vector. Techniques for constructing AAV vectorsthat express different capsid protein serotypes are within the skill inthe art; see, e.g., Rabinowitz, J. E., et al. (2002), J. Virol.76:791-801, the entire disclosure of which is incorporated herein byreference.

Selection of recombinant viral vectors suitable for use in theinvention, methods for inserting nucleic acid sequences for expressingRNA into the vector, methods of delivering the viral vector to the cellsof interest, and recovery of the expressed RNA products are within theskill in the art. See, for example, Dornburg (1995), Gene Therap.2:301-310; Eglitis (1988), Biotechniques 6:608-614; Miller (1990), Hum.Gene Therap. 1:5-14; and Anderson (1998), Nature 392:25-30, the entiredisclosures of which are incorporated herein by reference.

Particularly suitable viral vectors are those derived from AV and AAV. Asuitable AV vector for expressing the miR gene products, a method forconstructing the recombinant AV vector, and a method for delivering thevector into target cells, are described in Xia et al. (2002), Nat.Biotech. 20:1006-1010, the entire disclosure of which is incorporatedherein by reference. Suitable AAV vectors for expressing the miR geneproducts, methods for constructing the recombinant AAV vector, andmethods for delivering the vectors into target cells are described inSamulski et al. (1987), J. Virol. 61:3096-3101; Fisher et al. (1996), J.Virol., 70:520-532; Samulski et al. (1989), J. Virol. 63:3822-3826; U.S.Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International PatentApplication No. WO 94/13788; and International Patent Application No. WO93/24641, the entire disclosures of which are incorporated herein byreference. In one embodiment, the miR gene products are expressed from asingle recombinant AAV vector comprising the CMV intermediate earlypromoter.

In a certain embodiment, a recombinant AAV viral vector of the inventioncomprises a nucleic acid sequence encoding a miR precursor RNA inoperable connection with a polyT termination sequence under the controlof a human U6 RNA promoter. As used herein, “in operable connection witha polyT termination sequence” means that the nucleic acid sequencesencoding the sense or antisense strands are immediately adjacent to thepolyT termination signal in the 5′ direction. During transcription ofthe miR sequences from the vector, the polyT termination signals act toterminate transcription.

In other embodiments of the treatment methods of the invention, aneffective amount of at least one compound that inhibits miR expressioncan be administered to the subject. As used herein, “inhibiting miRexpression” means that the production of the precursor and/or active,mature form of miR gene product after treatment is less than the amountproduced prior to treatment. One skilled in the art can readilydetermine whether miR expression has been inhibited in a cancer cell,using, for example, the techniques for determining miR transcript leveldiscussed herein Inhibition can occur at the level of gene expression(i.e., by inhibiting transcription of a miR gene encoding the miR geneproduct) or at the level of processing (e.g., by inhibiting processingof a miR precursor into a mature, active miR).

As used herein, an “effective amount” of a compound that inhibits miRexpression is an amount sufficient to inhibit proliferation of a cancercell in a subject suffering from a cancer (e.g., AML cancer). Oneskilled in the art can readily determine an effective amount of a miRexpression-inhibiting compound to be administered to a given subject, bytaking into account factors, such as the size and weight of the subject;the extent of disease penetration; the age, health and sex of thesubject; the route of administration; and whether the administration isregional or systemic.

For example, an effective amount of the expression-inhibiting compoundcan be based on the approximate weight of a tumor mass to be treated, asdescribed herein. An effective amount of a compound that inhibits miRexpression can also be based on the approximate or estimated body weightof a subject to be treated, as described herein.

One skilled in the art can also readily determine an appropriate dosageregimen for administering a compound that inhibits miR expression to agiven subject, as described herein.

Suitable compounds for inhibiting miR gene expression includedouble-stranded RNA (such as short- or small-interfering RNA or“siRNA”), antisense nucleic acids, and enzymatic RNA molecules, such asribozymes. Each of these compounds can be targeted to a given miR geneproduct and interfere with the expression (e.g., by inhibitingtranslation, by inducing cleavage and/or degradation) of the target miRgene product.

For example, expression of a given miR gene can be inhibited by inducingRNA interference of the miR gene with an isolated double-stranded RNA(“dsRNA”) molecule which has at least 90%, for example at least 95%, atleast 98%, at least 99%, or 100%, sequence homology with at least aportion of the miR gene product. In a particular embodiment, the dsRNAmolecule is a “short or small interfering RNA” or “siRNA.”

siRNA useful in the present methods comprise short double-stranded RNAfrom about 17 nucleotides to about 29 nucleotides in length, preferablyfrom about 19 to about 25 nucleotides in length. The siRNA comprise asense RNA strand and a complementary antisense RNA strand annealedtogether by standard Watson-Crick base-pairing interactions (hereinafter“base-paired”). The sense strand comprises a nucleic acid sequence thatis substantially identical to a nucleic acid sequence contained withinthe target miR gene product.

As used herein, a nucleic acid sequence in an siRNA that is“substantially identical” to a target sequence contained within thetarget mRNA is a nucleic acid sequence that is identical to the targetsequence, or that differs from the target sequence by one or twonucleotides. The sense and antisense strands of the siRNA can comprisetwo complementary, single-stranded RNA molecules, or can comprise asingle molecule in which two complementary portions are base-paired andare covalently linked by a single-stranded “hairpin” area.

The siRNA can also be altered RNA that differs from naturally-occurringRNA by the addition, deletion, substitution and/or alteration of one ormore nucleotides. Such alterations can include addition ofnon-nucleotide material, such as to the end(s) of the siRNA or to one ormore internal nucleotides of the siRNA, or modifications that make thesiRNA resistant to nuclease digestion, or the substitution of one ormore nucleotides in the siRNA with deoxyribonucleotides.

One or both strands of the siRNA can also comprise a 3′ overhang. Asused herein, a “3′ overhang” refers to at least one unpaired nucleotideextending from the 3′-end of a duplexed RNA strand. Thus, in certainembodiments, the siRNA comprises at least one 3′ overhang of from 1 toabout 6 nucleotides (which includes ribonucleotides ordeoxyribonucleotides) in length, from 1 to about 5 nucleotides inlength, from 1 to about 4 nucleotides in length, or from about 2 toabout 4 nucleotides in length. In a particular embodiment, the 3′overhang is present on both strands of the siRNA, and is 2 nucleotidesin length. For example, each strand of the siRNA can comprise 3′overhangs of dithymidylic acid (“TT”) or diuridylic acid (“uu”).

The siRNA can be produced chemically or biologically, or can beexpressed from a recombinant plasmid or viral vector, as described abovefor the isolated miR gene products. Exemplary methods for producing andtesting dsRNA or siRNA molecules are described in U.S. Published PatentApplication No. 2002/0173478 to Gewirtz and in U.S. Published PatentApplication No. 2004/0018176 to Reich et al., the entire disclosures ofboth of which are incorporated herein by reference.

Expression of a given miR gene can also be inhibited by an antisensenucleic acid. As used herein, an “antisense nucleic acid” refers to anucleic acid molecule that binds to target RNA by means of RNA-RNA,RNA-DNA or RNA-peptide nucleic acid interactions, which alters theactivity of the target RNA. Antisense nucleic acids suitable for use inthe present methods are single-stranded nucleic acids (e.g., RNA, DNA,RNA-DNA chimeras, peptide nucleic acids (PNA)) that generally comprise anucleic acid sequence complementary to a contiguous nucleic acidsequence in a miR gene product. The antisense nucleic acid can comprisea nucleic acid sequence that is 50-100% complementary, 75-100%complementary, or 95-100% complementary to a contiguous nucleic acidsequence in a miR gene product. Nucleic acid sequences of particularhuman miR gene products are provided in the Tables herein. Withoutwishing to be bound by any theory, it is believed that the antisensenucleic acids activate RNase H or another cellular nuclease that digeststhe miR gene product/antisense nucleic acid duplex.

Antisense nucleic acids can also contain modifications to the nucleicacid backbone or to the sugar and base moieties (or their equivalent) toenhance target specificity, nuclease resistance, delivery or otherproperties related to efficacy of the molecule. Such modificationsinclude cholesterol moieties, duplex intercalators, such as acridine, orone or more nuclease-resistant groups.

Antisense nucleic acids can be produced chemically or biologically, orcan be expressed from a recombinant plasmid or viral vector, asdescribed above for the isolated miR gene products. Exemplary methodsfor producing and testing are within the skill in the art; see, e.g.,Stein and Cheng (1993), Science 261:1004 and U.S. Pat. No. 5,849,902 toWoolf et al., the entire disclosures of which are incorporated herein byreference.

Expression of a given miR gene can also be inhibited by an enzymaticnucleic acid. As used herein, an “enzymatic nucleic acid” refers to anucleic acid comprising a substrate binding region that hascomplementarity to a contiguous nucleic acid sequence of a miR geneproduct, and which is able to specifically cleave the miR gene product.The enzymatic nucleic acid substrate binding region can be, for example,50-100% complementary, 75-100% complementary, or 95-100% complementaryto a contiguous nucleic acid sequence in a miR gene product. Theenzymatic nucleic acids can also comprise modifications at the base,sugar, and/or phosphate groups. An exemplary enzymatic nucleic acid foruse in the present methods is a ribozyme.

The enzymatic nucleic acids can be produced chemically or biologically,or can be expressed from a recombinant plasmid or viral vector, asdescribed above for the isolated miR gene products. Exemplary methodsfor producing and testing dsRNA or siRNA molecules are described inWerner and Uhlenbeck (1995), Nucl. Acids Res. 23:2092-96; Hammann et al.(1999), Antisense and Nucleic Acid Drug Dev. 9:25-31; and U.S. Pat. No.4,987,071 to Cech et al, the entire disclosures of which areincorporated herein by reference.

Administration of at least one miR gene product, or at least onecompound for inhibiting miR expression, will inhibit the proliferationof cancer cells in a subject who has a cancer (e.g., AML). As usedherein, to “inhibit the proliferation of a cancer cell” means to killthe cell, or permanently or temporarily arrest or slow the growth of thecell Inhibition of cancer cell proliferation can be inferred if thenumber of such cells in the subject remains constant or decreases afteradministration of the miR gene products or miR geneexpression-inhibiting compounds. An inhibition of cancer cellproliferation can also be inferred if the absolute number of such cellsincreases, but the rate of tumor growth decreases.

The number of cancer cells in the body of a subject can be determined bydirect measurement, or by estimation from the size of primary ormetastatic tumor masses. For example, the number of cancer cells in asubject can be measured by immunohistological methods, flow cytometry,or other techniques designed to detect characteristic surface markers ofcancer cells.

The miR gene products or miR gene expression-inhibiting compounds can beadministered to a subject by any means suitable for delivering thesecompounds to cancer cells of the subject. For example, the miR geneproducts or miR expression-inhibiting compounds can be administered bymethods suitable to transfect cells of the subject with these compounds,or with nucleic acids comprising sequences encoding these compounds. Inone embodiment, the cells are transfected with a plasmid or viral vectorcomprising sequences encoding at least one miR gene product or miR geneexpression-inhibiting compound.

Transfection methods for eukaryotic cells are well known in the art, andinclude, e.g., direct injection of the nucleic acid into the nucleus orpronucleus of a cell; electroporation; liposome transfer or transfermediated by lipophilic materials; receptor-mediated nucleic aciddelivery, bioballistic or particle acceleration; calcium phosphateprecipitation, and transfection mediated by viral vectors.

For example, cells can be transfected with a liposomal transfercompound, e.g., DOTAP(N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methylsulfate,Boehringer-Mannheim) or an equivalent, such as LIPOFECTIN. The amount ofnucleic acid used is not critical to the practice of the invention;acceptable results may be achieved with 0.1-100 micrograms of nucleicacid/10⁵ cells. For example, a ratio of about 0.5 micrograms of plasmidvector in 3 micrograms of DOTAP per 10⁵ cells can be used.

A miR gene product or miR gene expression-inhibiting compound can alsobe administered to a subject by any suitable enteral or parenteraladministration route. Suitable enteral administration routes for thepresent methods include, e.g., oral, rectal, or intranasal delivery.Suitable parenteral administration routes include, e.g., intravascularadministration (e.g., intravenous bolus injection, intravenous infusion,intra-arterial bolus injection, intra-arterial infusion and catheterinstillation into the vasculature); peri- and intra-tissue injection(e.g., peri-tumoral and intra-tumoral injection, intra-retinalinjection, or subretinal injection); subcutaneous injection ordeposition, including subcutaneous infusion (such as by osmotic pumps);direct application to the tissue of interest, for example by a catheteror other placement device (e.g., a retinal pellet or a suppository or animplant comprising a porous, non-porous, or gelatinous material); andinhalation. Particularly suitable administration routes are injection,infusion and direct injection into the tumor.

In the present methods, a miR gene product or miR gene productexpression-inhibiting compound can be administered to the subject eitheras naked RNA, in combination with a delivery reagent, or as a nucleicacid (e.g., a recombinant plasmid or viral vector) comprising sequencesthat express the miR gene product or miR gene expression-inhibitingcompound. Suitable delivery reagents include, e.g., the Mints TransitTKO lipophilic reagent; LIPOFECTIN; lipofectamine; cellfectin;polycations (e.g., polylysine) and liposomes.

Recombinant plasmids and viral vectors comprising sequences that expressthe miR gene products or miR gene expression-inhibiting compounds, andtechniques for delivering such plasmids and vectors to cancer cells, arediscussed herein and/or are well known in the art.

In a particular embodiment, liposomes are used to deliver a miR geneproduct or miR gene expression-inhibiting compound (or nucleic acidscomprising sequences encoding them) to a subject. Liposomes can alsoincrease the blood half-life of the gene products or nucleic acids.Suitable liposomes for use in the invention can be formed from standardvesicle-forming lipids, which generally include neutral or negativelycharged phospholipids and a sterol, such as cholesterol. The selectionof lipids is generally guided by consideration of factors, such as thedesired liposome size and half-life of the liposomes in the bloodstream. A variety of methods are known for preparing liposomes, forexample, as described in Szoka et al. (1980), Ann. Rev. Biophys. Bioeng.9:467; and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and5,019,369, the entire disclosures of which are incorporated herein byreference.

The liposomes for use in the present methods can comprise a ligandmolecule that targets the liposome to cancer cells. Ligands that bind toreceptors prevalent in cancer cells, such as monoclonal antibodies thatbind to tumor cell antigens, are preferred.

The liposomes for use in the present methods can also be modified so asto avoid clearance by the mononuclear macrophage system (“MMS”) andreticuloendothelial system (“RES”). Such modified liposomes haveopsonization-inhibition moieties on the surface or incorporated into theliposome structure. In a particularly preferred embodiment, a liposomeof the invention can comprise both an opsonization-inhibition moiety anda ligand.

Opsonization-inhibiting moieties for use in preparing the liposomes ofthe invention are typically large hydrophilic polymers that are bound tothe liposome membrane. As used herein, an opsonization-inhibiting moietyis “bound” to a liposome membrane when it is chemically or physicallyattached to the membrane, e.g., by the intercalation of a lipid-solubleanchor into the membrane itself, or by binding directly to active groupsof membrane lipids. These opsonization-inhibiting hydrophilic polymersform a protective surface layer that significantly decreases the uptakeof the liposomes by the MMS and RES; e.g., as described in U.S. Pat. No.4,920,016, the entire disclosure of which is incorporated herein byreference.

Opsonization-inhibiting moieties suitable for modifying liposomes arepreferably water-soluble polymers with a number-average molecular weightfrom about 500 to about 40,000 daltons, and more preferably from about2,000 to about 20,000 daltons. Such polymers include polyethylene glycol(PEG) or polypropylene glycol (PPG) or derivatives thereof; e.g.,methoxy PEG or PPG, and PEG or PPG stearate; synthetic polymers, such aspolyacrylamide or poly N-vinyl pyrrolidone; linear, branched, ordendrimeric polyamidoamines; polyacrylic acids; polyalcohols, e.g.,polyvinylalcohol and polyxylitol to which carboxylic or amino groups arechemically linked, as well as gangliosides, such as ganglioside GM1.Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof,are also suitable. In addition, the opsonization-inhibiting polymer canbe a block copolymer of PEG and either a polyamino acid, polysaccharide,polyamidoamine, polyethyleneamine, or polynucleotide. Theopsonization-inhibiting polymers can also be natural polysaccharidescontaining amino acids or carboxylic acids, e.g., galacturonic acid,glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid,neuraminic acid, alginic acid, carrageenan; aminated polysaccharides oroligosaccharides (linear or branched); or carboxylated polysaccharidesor oligosaccharides, e.g., reacted with derivatives of carbonic acidswith resultant linking of carboxylic groups. Preferably, theopsonization-inhibiting moiety is a PEG, PPG, or a derivative thereof.Liposomes modified with PEG or PEG-derivatives are sometimes called“PEGylated liposomes.”

The opsonization-inhibiting moiety can be bound to the liposome membraneby any one of numerous well-known techniques. For example, anN-hydroxysuccinimide ester of PEG can be bound to aphosphatidyl-ethanolamine lipid-soluble anchor, and then bound to amembrane. Similarly, a dextran polymer can be derivatized with astearylamine lipid-soluble anchor via reductive amination usingNa(CN)BH₃ and a solvent mixture, such as tetrahydrofuran and water in a30:12 ratio at 60° C.

Liposomes modified with opsonization-inhibition moieties remain in thecirculation much longer than unmodified liposomes. For this reason, suchliposomes are sometimes called “stealth” liposomes. Stealth liposomesare known to accumulate in tissues fed by porous or “leaky”microvasculature. Thus, tissue characterized by such microvasculaturedefects, for example, solid tumors (e.g., AML cancers), will efficientlyaccumulate these liposomes; see Gabizon, et al. (1988), Proc. Natl.Acad. Sci., U.S.A., 18:6949-53. In addition, the reduced uptake by theRES lowers the toxicity of stealth liposomes by preventing significantaccumulation of the liposomes in the liver and spleen. Thus, liposomesthat are modified with opsonization-inhibition moieties are particularlysuited to deliver the miR gene products or miR geneexpression-inhibition compounds (or nucleic acids comprising sequencesencoding them) to tumor cells.

The miR gene products or miR gene expression-inhibition compounds can beformulated as pharmaceutical compositions, sometimes called“medicaments,” prior to administering them to a subject, according totechniques known in the art. Accordingly, the invention encompassespharmaceutical compositions for treating AML cancer. In one embodiment,the pharmaceutical composition comprises at least one isolated miR geneproduct, or an isolated variant or biologically-active fragment thereof,and a pharmaceutically-acceptable carrier. In a particular embodiment,the at least one miR gene product corresponds to a miR gene product thathas a decreased level of expression in AML cancer cells relative tosuitable control cells.

In other embodiments, the pharmaceutical compositions of the inventioncomprise at least one miR expression-inhibition compound. In aparticular embodiment, the at least one miR gene expression-inhibitioncompound is specific for a miR gene whose expression is greater in AMLcancer cells than control cells.

Pharmaceutical compositions of the present invention are characterizedas being at least sterile and pyrogen-free. As used herein,“pharmaceutical compositions” include formulations for human andveterinary use. Methods for preparing pharmaceutical compositions of theinvention are within the skill in the art, for example, as described inRemington's Pharmaceutical Science, 17th ed., Mack Publishing Company,Easton, Pa. (1985), the entire disclosure of which is incorporatedherein by reference.

The present pharmaceutical compositions comprise at least one miR geneproduct or miR gene expression-inhibition compound (or at least onenucleic acid comprising a sequence encoding the miR gene product or miRgene expression-inhibition compound) (e.g., 0.1 to 90% by weight), or aphysiologically-acceptable salt thereof, mixed with apharmaceutically-acceptable carrier. In certain embodiments, thepharmaceutical composition of the invention additionally comprises oneor more anti-cancer agents (e.g., chemotherapeutic agents). Thepharmaceutical formulations of the invention can also comprise at leastone miR gene product or miR gene expression-inhibition compound (or atleast one nucleic acid comprising a sequence encoding the miR geneproduct or miR gene expression-inhibition compound), which areencapsulated by liposomes and a pharmaceutically-acceptable carrier. Inone embodiment, the pharmaceutical composition comprises a miR gene orgene product that is not miR-15, miR-16, miR-143 and/or miR-145.

Especially suitable pharmaceutically-acceptable carriers are water,buffered water, normal saline, 0.4% saline, 0.3% glycine, hyaluronicacid and the like.

In a particular embodiment, the pharmaceutical compositions of theinvention comprise at least one miR gene product or miR geneexpression-inhibition compound (or at least one nucleic acid comprisinga sequence encoding the miR gene product or miR geneexpression-inhibition compound) that is resistant to degradation bynucleases. One skilled in the art can readily synthesize nucleic acidsthat are nuclease resistant, for example by incorporating one or moreribonucleotides that is modified at the 2′-position into the miR geneproduct. Suitable 2′-modified ribonucleotides include those modified atthe 2′-position with fluoro, amino, alkyl, alkoxy and O-allyl.

Pharmaceutical compositions of the invention can also compriseconventional pharmaceutical excipients and/or additives. Suitablepharmaceutical excipients include stabilizers, antioxidants, osmolalityadjusting agents, buffers, and pH adjusting agents. Suitable additivesinclude, e.g., physiologically biocompatible buffers (e.g., tromethaminehydrochloride), additions of chelants (such as, for example, DTPA orDTPA-bisamide) or calcium chelate complexes (such as, for example,calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions of calciumor sodium salts (for example, calcium chloride, calcium ascorbate,calcium gluconate or calcium lactate). Pharmaceutical compositions ofthe invention can be packaged for use in liquid form, or can belyophilized.

For solid pharmaceutical compositions of the invention, conventionalnontoxic solid pharmaceutically-acceptable carriers can be used; forexample, pharmaceutical grades of mannitol, lactose, starch, magnesiumstearate, sodium saccharin, talcum, cellulose, glucose, sucrose,magnesium carbonate, and the like.

For example, a solid pharmaceutical composition for oral administrationcan comprise any of the carriers and excipients listed above and 10-95%,preferably 25%-75%, of the at least one miR gene product or miR geneexpression-inhibition compound (or at least one nucleic acid comprisingsequences encoding them). A pharmaceutical composition for aerosol(inhalational) administration can comprise 0.01-20% by weight,preferably 1%-10% by weight, of the at least one miR gene product or miRgene expression-inhibition compound (or at least one nucleic acidcomprising a sequence encoding the miR gene product or miR geneexpression-inhibition compound) encapsulated in a liposome as describedabove, and a propellant. A carrier can also be included as desired;e.g., lecithin for intranasal delivery.

The pharmaceutical compositions of the invention can further compriseone or more anti-cancer agents. In a particular embodiment, thecompositions comprise at least one miR gene product or miR geneexpression-inhibition compound (or at least one nucleic acid comprisinga sequence encoding the miR gene product or miR geneexpression-inhibition compound) and at least one chemotherapeutic agent.Chemotherapeutic agents that are suitable for the methods of theinvention include, but are not limited to, DNA-alkylating agents,anti-tumor antibiotic agents, anti-metabolic agents, tubulin stabilizingagents, tubulin destabilizing agents, hormone antagonist agents,topoisomerase inhibitors, protein kinase inhibitors, HMG-CoA inhibitors,CDK inhibitors, cyclin inhibitors, caspase inhibitors, metalloproteinaseinhibitors, antisense nucleic acids, triple-helix DNAs, nucleic acidsaptamers, and molecularly-modified viral, bacterial and exotoxic agents.Examples of suitable agents for the compositions of the presentinvention include, but are not limited to, cytidine arabinoside,methotrexate, vincristine, etoposide (VP-16), doxorubicin (adriamycin),cisplatin (CDDP), dexamethasone, arglabin, cyclophosphamide, sarcolysin,methylnitrosourea, fluorouracil, 5-fluorouracil (5FU), vinblastine,camptothecin, actinomycin-D, mitomycin C, hydrogen peroxide,oxaliplatin, irinotecan, topotecan, leucovorin, carmustine,streptozocin, CPT-11, taxol, tamoxifen, dacarbazine, rituximab,daunorubicin, 1-β-D-arabinofuranosylcytosine, imatinib, fludarabine,docetaxel and FOLFOX4.

The invention also encompasses methods of identifying an anti-AML canceragent, comprising providing a test agent to a cell and measuring thelevel of at least one miR gene product in the cell. In one embodiment,the method comprises providing a test agent to a cell and measuring thelevel of at least one miR gene product associated with decreasedexpression levels in AML cancer cells. An increase in the level of themiR gene product in the cell, relative to a suitable control (e.g., thelevel of the miR gene product in a control cell), is indicative of thetest agent being an anti-AML cancer agent.

In a particular embodiment, the at least one miR gene product associatedwith decreased expression levels in AML cancer cells is selected fromthe group consisting of the miRNAs as shown in any one of FIGS. 5-6,8-18 and 21 (Tables 1-2, 5-15 and 18) and a combination thereof.

In other embodiments the method comprises providing a test agent to acell and measuring the level of at least one miR gene product associatedwith increased expression levels in AML cancer cells. A decrease in thelevel of the miR gene product in the cell, relative to a suitablecontrol (e.g., the level of the miR gene product in a control cell), isindicative of the test agent being an anti-AML cancer agent.

In a particular embodiment, at least one miR gene product associatedwith increased expression levels in AML cancer cells is selected fromthe group consisting of miR-20, miR-25, miR-191, miR-199a, and miR-199band a combination thereof.

Suitable agents include, but are not limited to drugs (e.g., smallmolecules, peptides), and biological macromolecules (e.g., proteins,nucleic acids). The agent can be produced recombinantly, synthetically,or it may be isolated (i.e., purified) from a natural source. Variousmethods for providing such agents to a cell (e.g., transfection) arewell known in the art, and several of such methods are describedhereinabove. Methods for detecting the expression of at least one miRgene product (e.g., Northern blotting, in situ hybridization, RT-PCR,expression profiling) are also well known in the art. Several of thesemethods are also described herein.

The invention will now be illustrated by the following non-limitingexamples.

EXEMPLIFICATION Methods

Patients and cell samples. Leukemic samples from 158 patients with newlydiagnosed AML and 54 samples from patients with AML at relapse(34) orwith refractory disease (20) were obtained from the Cell and Tissue Bankat MD Anderson Cancer Center (n=202) and Thomas Jefferson University(n=10), after informed consent was signed according to institutionalguidelines (FIG. 4 (Table 1)).

Bone marrow or peripheral blood samples were collected, prepared byFicoll-Hypaque (Nygaard) gradient centrifugation and cryopreserved.Cytogenetic analyses of the samples were performed at presentation, aspreviously described¹⁶. The criteria used to describe a cytogeneticclone and karyotype followed the recommendations of the InternationalSystem for Human Cytogenetic Nomenclature¹⁷. An independent set of 36patients with AML was used to validate miRNAs within the microarraysignatures by using qRT-PCR (FIG. 4 (Table 1)). Complete remission (CR)was defined by the presence of <than 5% of blasts in the bone marrowaspirate, absolute peripheral neutrophil count >1×10⁹/l and platelets>100×10⁹/l.

Peripheral blood mature granulocytes and monocytes, bone marrow CD71+selected erythrocytes precursors and CD34+ cells from 4 healthy donors,except for CD34+ (10 donors) were purchased from Allcells. In vitrodifferentiated megakaryocytes were obtained as previously described¹⁸.

RNA extraction and miRNA micro array experiments.

RNA extraction and miRNA microchip experiments were performed asdescribed in detail elsewhere¹⁹. Briefly, 5 ug of total RNA from 176 AMLpatients were hybridized in quadruplicate with probes corresponding to250 human mature and precursor miRNAs (as described in the miRBase(http://microrna.sanger.ac.uk/) on November 2005)²⁰.

Real-Time quantification of microRNAs.

The single tube TaqMan miRNAs as previously described²¹ using PCR 9700Thermocycler ABI Prism 7900HT and the sequence detection system (AppliedBiosystems) was selected because it had the least expression variabilityin the microarray patient data set. Comparative real-time PCR wasperformed in triplicate, including no-template controls. Relativeexpression was calculated using the comparative C_(t) method

Data Analysis.

Microarray images were analyzed using GENEPIX PRO. Average values of thereplicate spots of each miRNA were background subtracted, log2transformed, normalized and retained in the expression table whenmeasured as present in at least 10% of the samples. Normalization wasperformed over a set of housekeeping genes (FIG. 7 (Table 4)) printedonto the chip interspersed through the miRNA probes. In two classcomparisons (i.e., CD34 vs. AML) differentially expressed miRNAs wereidentified by using the test procedure within the Significance Analysisof Microarrays (SAM)²². SAM calculates a score for each gene on thebasis of the change of expression relative to the standard deviation ofall measurements. Since this is a multiple test, permutations areperformed to calculate the false discovery rate (FDR) or q-value. miRNAswith FDRs less than 5% and fold changes more than 2 were considered forfurther analysis. All data were submitted to the Array Express databasewith the use of MIAMExpress (accession numbers pending).

Statistical Analysis.

Fisher's exact test, t-Test and chi-square were used to compare baselinecharacteristics and average miRNA expression between groups of patients.All reported P values were two-sided and obtained using the SPSSsoftware package (SPSS 10.0). Overall survival was calculated from thetime of diagnosis until the date of last follow up and event-freesurvival (EFS) from the time of diagnosis until relapse or death. Datawere censored for patients who were alive at the time of last follow up.To perform the survival and generate a Kaplan-Meier (KM) plot, miRNAlevels measured on the chips and by qRT-PCR were converted into discretevariables by splitting the samples in two classes (high and lowexpression, according to the median expression in the full set ofsamples). Survival curves were obtained for each group and compared byusing the log-rank test. Hazard Ratios with their 95% confidentintervals obtained from the KM method are also reported.

Target Prediction and Microarray Validation

Data validation. To validate the microarray data we used Pearsoncorrelation and linear regression analysis (SPSS software) using 42miRNA measurements in 10 patients. These functions examine each pair ofmeasurements (one from the chip and the other from RT-PCR) to determinewhether the two variables tend to move together, that is whether thelarge r values from the chip (high expression) are associated with thelower values from the qRT-PCR (delta Ct). A negative correlation isexpected because the qRT-PCR values (delta Ct) are inversed to theexpression levels of miRNAs. Log values for both chip and qRT-PCR miRNAmeasurements were used.

Target prediction. MicroRNA targets were predicted in silico by usingTARGETSCAN³² (www.genes.mit.edu/targetscan) and PICTAR³³(www.pictar.bio.nyu.edu); both databases predict conserved 3′UTR miRNAtargets.

Results

AML patients reveal a distinct spectrum of miRNA expression with respectto normal CD34+ progenitor cells.

As a first step to wards understanding the possible involvement ofmiRNAs in the pathogenesis of AML, we analyzed the miRNA expression in122 newly diagnosed AML patient samples and CD34+ cells from 10different donors using a miRNA microarray platform¹⁹ (Clinical data inFIG. 4 (Table 1)). SAM identified only down-regulated miRNAs in AMLsamples compared with CD34+ cells (Table S 2, supporting information).We confirmed many of these differentially expressed miRNAs by usingqRT-PCR (FIG. 1A). Additionally, to validate the microarray platform weperformed qRT-PCR for miRNAs that were highly, intermediate and lowexpressed on the chip. As shown in FIG. 1B the miRNA levels measured byeither the microarray or the qRT-PCR were very concordant and there wasa highly significant correlation between the measures in the twoplatforms (r=0.88, p<0.0 01).

A miRNA signature correlates with hematopoietic differentiation and FABclassification

miRNA expression has been shown to be informative of the hematopoieticdevelopmental lineage and differentiation stage of tumors¹¹. Asdifferent profiles characterize normal vs. malignant cells in AMLpatients, we determine d by qRT-PCR the expression pattern of the mostdifferentially expressed miRNAs between AML samples and CD34+ cellsamong a panel of human hematopoietic cells, including mature granulocytes and monocyte s, as well as erythrocyte and megakaryocyte precursors.Many miRNAs down-regulated in AML were also down-regulated in mature andprecursor hematopoietic cells (FIGS. 1C and 3A). Two recent studies havedescribed widespread miRNA down-regulation during in vitrodifferentiation of CD34+ cells to several lineages^(18, 23). Theseresults suggest that a subset of miRNAs in leukemia follow closely thedifferentiation patterns of miRNA expression in normal hematopoiesis. IfmiRNAs reflect the stage of cell differentiation in leukemia patients,they should also correlate with the French-American and British (FAB)classification of AML²⁴, which is based on cytomorphology andimmunophenotype, both closely associated with the differentiation stageof the leukemia. Indeed, we identified signatures associated with FABclassification. (FIGS. 9-12, Tables 6-9). Within the FAB M 0-M1signature, we identified several miR-181 family members, as well asother miRNAs highly expressed in CD34+ cells, suggesting an expressionprofile closer to that of stem cells (FIG. 9 (Table 6)). The expressionof miR-181b is in fact down-regulated in mature and committed precursorshematopoietic cells from all lineages (FIG. 3A) and similar results wereobserved in the most differentiated leukemias like FAB M6-M7 (FIG. 1D).

MiRNAs Positively Correlated with White Blood Cell and Blasts Counts

We then investigated whether miRNAs are associated with pretreatmentpatient characteristics such as age, sex, white blood cell (WBC) count,bone marrow or peripheral blood blasts percentage. We detected apositive correlation in several miRNAs, including miR-155, miR-30b,miR-30c, miR-25 and miR-181b with WBC count, peripheral blood and marrowblast percentage (FIG. 13 (Table 10)).

MicroRNA Signatures Associated with Defined Cytogenetic Subgroups.

To identify miRNA s associated with known cytogenetic abnormalities inAML we studied 116 AML samples with at least 20 metaphases analyzed byconventional karyotype by using permutation adjusted t-tests within SAM.These data are summarized in FIG. 5 (Table 2).

AML with Normal Karyotype.

We identified a signature distinguishing AML cases with a normalkaryotype from all other cases of AML with abnormal karyotype (FIG. 14(Table 11), FIG. 3B). Among the up-regulated genes, miR are locatedwithin the cluster of HOX genes, which have been shown to be overexpressed in AML with a normal karyotype 6 (FIG. 1E, FIG. 5 (Table 2)).In particular, we and others have shown that Hox embedded miRNAs likemiR-10a and miR-196b target several Hox genes, revealing a complex layerof regulation for this family of transcription factors^(18, 25).

Two previous studies identified high levels of expression of the DNAmethyl transferase genes DNMT3A and 3B in normal karyotype AML samplessuggesting a potential role for abnormal methylation in the pathogenesisof this subtype⁵⁻⁶. Intriguingly, among the down-regulated miRNAs in thenormal karyotype group, are present two miRNAs (miR-200c and miR-182),predicted to target DNMT3A and miR-, which is proposed to target DNMT3B.Thus, the down-regulation of these miRNAs may contribute to the overexpression of both DNMT3 genes in normal karyotype AML cells.

11q23 Abnormalities

Among the genes down-regulated in patients with t(9; 11) [5] and t(6;11)[4] (FIG. 15 (Table 12)), many are predicted to target Hox geneswhich have been described over-expressed and associated with poorprognosis in this group of patients, i.e., HOXA9 (let7f), HOSA10(iR-15a), PBX3(let07f, miR-15a and miR-196b) and MEISI (miR-331)⁶ (FIG.15 (Table 12)). Likewise, members of the miR-29 family, alsodown-regulated in this group, are predicted to target the anti-apoptoticMCLI gene

Complex Karyotype

Samples with 3 or more cytogenetics abnormalities share a commonsignature that includes miR-126, miR-26a, miR-34b, miR-30c and miR-301as the most discriminative genes for this group. (FIG. 16 (Table 13)).Likewise in patients with isolated loss of the chromosome 7, miR-126 wasup-regulated (Table S11). Interestingly this miRNA is highly expressedin CD34+ stem cells and down-regulated in other AMLs, except in thosewith complex karyotype. These results were confirmed in an independentset of AML patients with complex (N=6) and non-complex cytogeneticabnormalities (N=22) by using qRT-PCR (FIG. 1F).

Trisomy 8

The signature obtained using SAM identified many up-regulated miRNAs inpatient samples with isolated trisomy 8 (FIG. 18 (Table 15)). Among theup-regulated miRNAs, miR124a and miR-30d are located at 8p21 and 8q23respectively, suggesting that a gene dosage effect may play a role inthe up-regulation of these miRNAs.

MicroRNAs Expression in Relapsed AML Patients

We further investigated miRNAs expression profiles of 54 patients withrelapsed acute myeloid leukemia by using our miRNA platform (FIG. 19(Table 16)). We did not find strong differences between new and treatedpatients, as reflected by non-significant statistical scores and foldchange s lower than 2 (data not shown). However, we observed in thesepatients FAB and cytogenetics signatures highly similar to those of thenew patients (FIGS. 8-17; Tables 5-14), thus confirming the previouslydescribed findings. These data suggest that miRNAs expression is largelydriven by the differentiation stage of the leukemia and cytogenetics.

MicroRNAs Associated with the Outcome

We identified a small number of miRNAs with a false discovery rate lowerthan 1% and a SAM survival score (Cox regression) higher than 2associated with overall survival in 122 newly diagnosed AML patients.All the identified genes: miR-17-5p, MIR-20, miR-miR-182, miR-191,miR-199a and miR-199b when over-expressed, adversely affected overallsurvival (FIG. 6 (Table 3)). We then estimated the survivalprobabilities of the 122 AML patients with high or low expression of theabove miRNAs by using Kaplan-Meier method and log-rank test for survivalcurves comparisons. We confirmed the SAM results for miR-20 (FIG. 2A),miR-25 (FIG. 2B), miR-191, miR-199a and miR-199b, except for miR-17-5pand miR-182(p=0.06) [Data not shown]. To assess whether and by usingqRT-PCR in an independent sample of 36 patients with AML, we measuredmiR-20 and miR-25 by using qRT-PCR in an independent sample of 36patients with AML.

Patients with high expression of miR-20 or miR-25 were found to havesignificant shorter overall survival (OS) (FIGS. 2A and 2B) andevent-free survival (miR-20 p=0.012, HR=2.39 CI 95%:1.3-5.2 and miR-25p=0.018, HR=2.23 CI 95%:1.7-4.9) than AML patients with low expression.None of the other clinical characteristics, including sex, age,unfavorable cytogenetics, white blood cells and peripheral blasts countswere significantly associated with survival in this independent set of36 AML patients (data not shown).

MiRNAs Associated with Failure to Achieve Remission with InductionTreatment

As we had shown that biological and genetic findings in AML patientscorrelated with expression of different miRNAs, we then furtherinvestigated the relation between treatment response and miRNAexpression. To identify miRNAs associated with induction treatmentresponse, we analyzed the expression of miRNAs in a group of 24 AMLpatients at diagnosis, all treated with idarubicin 12 mg/m2 daily ondays 1 to 3 and cytarabine 1500 mg/m2 continuous infusion for 4 days(FIG. 20 (Table 17)). SAM identified 2 5 miRNAs down-regulated atdiagnosis in patients who had treatment failure (FIG. 21 (Table 18)).Among them, miR-29b and miR-29c are predicted to target MCLI, a geneassociated with resistance to a variety of chemotherapeutic agents²⁶. Toconfirm these results, we measured miR-29b by qRT-PCR in an independentset of AML patients with similar baseline characteristics but treatedwith various chemotherapy protocols. We found that miR-29b isdown-regulated in patients with treatment induction failure comparedwith patients who achieve complete remission (FIG. 3C).

Discussion

In this study we used a microarray platform to perform genome widemiRNome analysis of AML samples and their progenitor CD34+ cells.Despite the fact that some miRNAs were up-regulated in AML patientscompared with CD34+ cells, most of the miRNAs were down-regulated. Someof the down-regulated miRNAs include markers for the differentiationstage of the leukemia that correlate well with the FAB classification ofAML. Lu et al. reported that miRNAs reflect the developmental lineageand differentiation state of tumors 11. Whether the miRNA subsetsidentified here are only markers for the differentiation stage or someof these miRNAs have a pathogenic role remains to be elucidated.

Using SAM, we identified molecular signatures associated with severalcytogenetic group s. Among the strongest signatures were thoseassociated to 11q23 rearrangements, normal karyotype and trisomy 8.

A Subset of miRNAs Acts as Oncogenic miRNAs.

The up-regulated cluster spanning miR-17 and miR-20, target E2FI²⁷, thusimpacting over the cell cycle regulation. In contrast, members of themiR-29 family, down-modulated in AML and associated with failure toachieve remission, is predicted to target MCLI, a critical apoptosisregulator, found up-regulated in cells that are resistant to a varietyof chemotherapeutic agents²⁶. Moreover other members of this family havebeen identified in the signature associated with short event-freesurvival in CLL patients 28 and in AML cancer 29, indicating that thismiRNA could be a tumor suppressor non-coding gene.

We describe molecular signatures associated with overall and event-freesurvival (OS). Several observations strengthen our results. First, weidentified miRNAs associated with survival despite the overall poorprognosis and short survival of the patients studied where outcomedifferences would be difficult to demonstrate. Second, two of the miRNAsassociated with survival (miR-20 and miR-25) were also correlated withhigh WBC and blast counts, all features closely relate d with survival.Third, we identified several up-regulated miRNAs in common with theshared signatures of six solid cancers (such as miR-17, miR-20 andmiR-191)¹⁰ some of them (like miR-17 and miR-20) with well characterizedroles in oncogenesis²⁷⁻³⁰.

In summary, we demonstrate s that a subset of miRNAs are markers for thedifferentiation stage of the leukemia and correlate with the FABclassification, while others are clearly deregulated in AML, associate dwith cytogenetic groups and outcome. Finally, we show that miRNAs may beinvolved in leukemogenesis acting as oncogenes and tumor suppressors.

The foregoing embodiments and advantages are merely exemplary and arenot to be construed as limiting the present invention. The presentteaching can be readily applied to other types of apparatuses. Thedescription of the present invention is intended to be illustrative, andnot to limit the scope of the claims Many alternatives, modifications,and variations will be apparent to those skilled in the art. In theclaims, means-plus-function clauses are intended to cover the structuresdescribed herein as performing the recited function and not onlystructural equivalents but also equivalent structures.

All scientific and patent publications referenced herein are herebyincorporated by reference. The invention having now been described byway of written description and example, those of skill in the art willrecognize that the invention can be practiced in a variety ofembodiments, that the foregoing description and example is for purposesof illustration and not limitation of the following claims.

The relevant teachings of all publications cited herein that have notexplicitly been incorporated by reference, are incorporated herein byreference in their entirety. While this invention has been particularlyshown and described with references to preferred embodiments thereof, itwill be understood by those skilled in the art that various changes inform and details may be made therein without departing from the scope ofthe invention encompassed by the appended

REFERENCES

-   1. Lowenberg B, Downing J. R., Burnett A. Acute Myeloid leukemia.    NEnglJMed 1999; 341: 1051-1062.-   2. Grimwade D, Haferlach T. Gene expression profiling in acute    myeloid leukemia. NEnglJMed 2004; 350:1676-7.-   3. Burnett A K. Current controversies: which patients with acute    myeloid leukemia should receive bone marrow transplantation? An    adult theater's view. Br. J Haematol 2002; 118:357-64.-   4. Drobyski W R. The role of allogeneic transplantation in high-risk    acute myeloid leukemia. Leukemia 2004; 10: 1565-8.-   5. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression    profiling to identify prognostic subclasses in adult acute myeloid    leukemia. NEngJMed 2004; 350:1605-1 61 6.-   6. Valk P J M, Verhaak G W, Beijen M A. Prognostically useful    gene-expression profiles in acute myeloid leukemia. NEngJMed 2004;    350: 1617-1628.-   7. Pasquinelli A E, Hunter S, Bracht J. MicroRNAs: a developing    story. Curr O, Genet Dev 2005; 15: 200-5.-   8. Bartel D. MicroRNAs: genomics, Biogenesis, Mechanism, and    Function. Cell 2004; 116:281-297.-   9. Chen C Z, Li L, Lodish H, Bartel D. MicroRNAs Modulate    Hematopoietic lineage Differentiation. Science 2004; 303:83-86.-   10. Volinia S, Calin G, Liu C G, et al. A microRNA expression    signature in human solid tumors defines cancer targets. Proc Nad    Acad Sci USA 2006; 103: 2257-61.-   11. Lu J, Getz G, Miska E A, et al. MicroRNA expression profiles    classify human cancers. Nature 2005; Jun. 9; 435: 834-8.-   12. Calin G A, Liu C G, Sevignani C, et al. MicroRNA profiling    reveals distinct signatures in B-Cell Chronic Lymphocytic leukemias.    Proc Nad Acad Sci USA 2004; 101: 11755-60.-   13. Eis PS, Tam W, Sun, L. Accumulation of miR-155 and BIC RNA in    human B cell lymphomas. Proc Nad Acad Sci USA 2005; 102: 3627-32.-   14. Metzler M, Wilda M, Busch K, et al. High expression of    miR-155/BIC RNA in children with Burkitt lymphoma. Genes Chomosomes    and Cancer 2004; 39:167-9.-   15. Costinean, S. et al. Pre B cell proliferation and lymphoblastic    leukemia/high grade lymphoma in Eμ miR155 transgenic mice. Proc Nad    Acad Sci USA 2006; 103: 7024-9.-   16. Bloomfield CD. Prognostic factors for selecting curative therapy    for adult acute myeloid leukemia. Leukemia 1992; 6:65-67. 21.-   17. An International System for Human Cytogenetic    Nomenclature (1985) ISCN 1985. Report of the Standing Committee on    Human Cytogenetic Nomenclature. Bi Orig Artic Ser 1985; 21:1-117.-   18. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNAs fingerprints    during human megakaryocytopoiesis. Proc Nad Acad Sci USA 2006; 103:    5078-83.-   19. Liu C G, Calin G A, Meloon B, et al. An oligonucleotide    microchip for genomic-wide microRNA profiling in human and mouse    tissues. Proc Nad Acad Sci USA 2004; 101: 11755-60.-   20. Griffiths-Jones S. The microRNA registry. Nucleic Acids Res    2004; 32, Database issue D109-D111.-   21. Chen C, Ridzon D A, Broomer A J, et al. Real-Time quantification    of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005:33:e179.-   22. Tusher V G, Tibshirani R, Chu G. Significant analysis of    microarrays applied to the ionizing radiation response. Proc Natl    Acad Sci USA 2001; 98:5116:21.-   23. Felli N, Pelosi E, Beta R, et al. Lineage-Specific Expression    and functional Relevance of MicroRNA genes in Normal Hematopoiesis.    Blood (ASH national meetings abstract) 2006; 106: 2263.-   24. French-American-British (FAB) Cooperative Group. Proposed    revised criteria for the classification of acute myeloid leukemia.    Ann Intern Med. 1985; 103:620-685.-   25. Yekta S, Shih I H, Bartel D P. Micro-RNA direct cleavage of    HOXB8 mRNA. Science 2004; 304:594-6.-   26. Zhou P, Qian L, Kozopas K M, Craig R W: Mcl-1, a Bcl-2 family    member, delays the death of hematopoietic cells under a variety of    apoptosis-inducing conditions. Blood 1997; 89:630.-   27. O'Donnell K A, Wentzel E A, Zeller K I, Dang C V, Mendell J T.    C-myc regulated microRNAs modulate E2F1 expression. Nature 2005;    435:839-43.-   28. Calin G A, Terracing M, Camino A, et al. A MicroRNA signature    associated with prognosis and progression in chronic lymphocytic    leukemia. NEnglJMed. 2005; 353:1793-801.-   29. Yanaihara N, Caplen N, Bowman, E, et al. Unique microRNA    molecular profiles in AML cancer diagnosis and prognosis. Cancer    Cell 2006; 9:189-98.-   30. He L, Thomson J M, Hemann M T. A microRNA polycistron as a    potential oncogene. re 2005; 435: 828-33.-   31. Lewis B P, Shih I H, Jones-Rhoades M W, Bartel P, Burge C B.    Prediction of mammalian microRNA targets. Cell 2003; 115:787-798.32.    Krek A, Grün D, Poy M, et al. Combinatorial microRNA target Nature G    37: 495-500.-   32. Lewis B P, Burge C B, Bartel D. Conserved seed pairing often    flanked by adenosines, indicates that thousands of human genes are    microRNA targets. Cell 2005; 120:15-20.-   33. Krek A, Grun D, Poy M N, et al. Combinatorial microRNA target    predictions. Nat. Genet. 2005; 37: 495-500.

1. A method of determining survival prognosis in a subject with acutemyeloid leukemia (AML), comprising: measuring the level of at least onemiR-182 gene product in a test sample from a subject with AML, anddetermining the subject's survival prognosis, wherein, if the level ofthe miR-182 gene product in the test sample is higher relative to thelevel of a corresponding miR-182 gene product in a control sample, thesubject is determined to have a shorter overall survival prognosis. 2.The method of claim 1, which further comprises measuring the level of atleast one miR gene product selected from the group consisting of:miR-20, miR-25, miR-191, miR-199a, and miR-199b and combinationsthereof.
 3. The method of claim 1, wherein the level of the at least onemiR gene product in the test sample is less than the level of thecorresponding miR gene product in the control sample.
 4. The method ofclaim 1, wherein the level of the at least one miR gene product in thetest sample is greater than the level of the corresponding miR geneproduct in the control sample.
 5. A method of determining the prognosisof a subject with acute myeloid leukemia, comprising: measuring thelevel of at least one miR-182 gene product in a test sample from saidsubject, wherein: the miR-182 gene product is associated with an adverseprognosis in AML; and an increase in the level of the at least onemiR-182 gene product in the test sample, relative to the level of acorresponding miR-182 gene product in a control sample, is indicative ofan adverse prognosis.
 6. A method of claim 1, comprising: (1) reversetranscribing miR-182 RNA from a test sample obtained from the subject toprovide a set of target oligodeoxynucleotides; (2) hybridizing thetarget oligodeoxynucleotides to a microarray comprising miR-182miRNA-specific probe oligonucleotides to provide a hybridization profilefor the test sample; and (3) comparing the test sample hybridizationprofile to a hybridization profile generated from a control sample,wherein an increase in the signal of at least one miR-182 miRNA isindicative of the subject either having, or being at risk fordeveloping, shorter overall survival-type AML.
 7. A method of claim 5,comprising: (1) reverse transcribing miR-182 RNA from a test sampleobtained from the subject to provide a set of targetoligodeoxynucleotides; (2) hybridizing the target oligodeoxynucleotidesto a microarray comprising miR-182 miRNA-specific probe oligonucleotidesto provide a hybridization profile for said test sample; and (3)comparing the test sample hybridization profile to a hybridizationprofile generated from a control sample, wherein an increase in thesignal is indicative of the subject either having, or being at risk fordeveloping, AML with an adverse prognosis.
 8. A method of determiningsurvival prognosis in a subject with acute myeloid leukemia (AML),comprising: measuring the level of at least one miR-191 gene product ina test sample from a subject with AML, and determining the subject'ssurvival prognosis, wherein, if the level of the miR-191 gene product inthe test sample is higher relative to the level of a correspondingmiR-191 gene product in a control sample, the subject is determined tohave a shorter overall survival prognosis.
 9. The method of claim 8,which further comprises measuring the level of at least one miR geneproduct selected from the group consisting of: miR-20, miR-25, miR-182,miR-199a, and miR-199b and combinations thereof.
 10. The method of claim8, wherein the level of the at least one miR gene product in the testsample is less than the level of the corresponding miR gene product inthe control sample.
 11. The method of claim 8, wherein the level of theat least one miR gene product in the test sample is greater than thelevel of the corresponding miR gene product in the control sample.
 12. Amethod of determining the prognosis of a subject with acute myeloidleukemia, comprising: measuring the level of at least one miR-191 geneproduct in a test sample from said subject, wherein the miR-191 geneproduct is associated with an adverse prognosis in AML; and an increasein the level of the at least one miR-191 gene product in the testsample, relative to the level of a corresponding miR-191 gene product ina control sample, is indicative of an adverse prognosis.
 13. A method ofclaim 8, comprising: (1) reverse transcribing miR-191 RNA from a testsample obtained from the subject to provide a set of targetoligodeoxynucleotides; (2) hybridizing the target oligodeoxynucleotidesto a microarray comprising miR-191 miRNA-specific probe oligonucleotidesto provide a hybridization profile for the test sample; and (3)comparing the test sample hybridization profile to a hybridizationprofile generated from a control sample, wherein an increase in thesignal of at least one miR-191 miRNA is indicative of the subject eitherhaving, or being at risk for developing, shorter overall survival-typeAML.
 14. A method of claim 12, comprising: (1) reverse transcribingmiR-182 RNA from a test sample obtained from the subject to provide aset of target oligodeoxynucleotides; (2) hybridizing the targetoligodeoxynucleotides to a microarray comprising miR-182 miRNA-specificprobe oligonucleotides to provide a hybridization profile for said testsample; and (3) comparing the test sample hybridization profile to ahybridization profile generated from a control sample, wherein anincrease in the signal is indicative of the subject either having, orbeing at risk for developing, AML with an adverse prognosis.
 15. Amethod of determining survival prognosis in a subject with acute myeloidleukemia (AML), comprising: measuring the level of at least one miR-199agene product in a test sample from a subject with AML, and determiningthe subject's survival prognosis, wherein, if the level of the miR-199agene product in the test sample is higher relative to the level of acorresponding miR-199a gene product in a control sample, the subject isdetermined to have a shorter overall survival prognosis.
 16. The methodof claim 15, which further comprises measuring the level of at least onemiR gene product selected from the group consisting of: miR-20, miR-25,miR-191, miR-182, and miR-199b and combinations thereof.
 17. The methodof claim 15, wherein the level of the at least one miR gene product inthe test sample is less than the level of the corresponding miR geneproduct in the control sample.
 18. The method of claim 15, wherein thelevel of the at least one miR gene product in the test sample is greaterthan the level of the corresponding miR gene product in the controlsample.
 19. A method of determining the prognosis of a subject withacute myeloid leukemia, comprising: measuring the level of at least onemiR-199a gene product in a test sample from said subject, wherein: themiR-199a gene product is associated with an adverse prognosis in AML;and an increase in the level of the at least one miR-199a gene productin the test sample, relative to the level of a corresponding miR-199agene product in a control sample, is indicative of an adverse prognosis.20. A method of claim 15, comprising: (1) reverse transcribing miR-199aRNA from a test sample obtained from the subject to provide a set oftarget oligodeoxynucleotides; (2) hybridizing the targetoligodeoxynucleotides to a microarray comprising miR-199a miRNA-specificprobe oligonucleotides to provide a hybridization profile for the testsample; and (3) comparing the test sample hybridization profile to ahybridization profile generated from a control sample, wherein anincrease in the signal of at least one miR-199a miRNA is indicative ofthe subject either having, or being at risk for developing, shorteroverall survival-type AML.
 21. A method of claim 19, comprising: (1)reverse transcribing miR-199a RNA from a test sample obtained from thesubject to provide a set of target oligodeoxynucleotides; (2)hybridizing the target oligodeoxynucleotides to a microarray comprisingmiR-199a miRNA-specific probe oligonucleotides to provide ahybridization profile for said test sample; and (3) comparing the testsample hybridization profile to a hybridization profile generated from acontrol sample, wherein an increase in the signal is indicative of thesubject either having, or being at risk for developing, AML with anadverse prognosis.